Published Technical Disclosure Archive

Personalized Cancer Therapy Platform using OPCML Fragment and AI

Publication ID: 24-11857624_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Personalized Cancer Therapy Platform using OPCML Fragment and AI,” Published Technical Disclosure No. 24-11857624_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857624_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,624.

Summary of the Inventive Concept

A novel system integrating OPCML fragment-based cancer therapy with AI-driven predictive modeling, IoT-enabled biosensors, blockchain-based data sharing, and novel nanomaterials for targeted delivery, enabling personalized and effective cancer treatment.

Background and Problem Solved

Cancer treatment is a complex and challenging field, with current methods often lacking personalized approaches. The original patent disclosed the use of OPCML fragment for cancer therapy, but it had limitations in terms of efficacy, dosage, and treatment duration. The new inventive concept addresses these limitations by synergistically combining the OPCML fragment with other distinct technologies.

Detailed Description of the Inventive Concept

The new system consists of four key components: 1) AI-based predictive modeling for personalized therapy, utilizing genomic profiles of patients with ovarian cancer; 2) IoT-enabled biosensors for real-time monitoring of cancer biomarkers, detecting changes in OPCML expression levels; 3) a blockchain-based platform for secure sharing of OPCML-related research data and collaboration among researchers; and 4) a novel composition of matter comprising OPCML fragment and a targeted delivery nanomaterial. These components work together to provide a comprehensive and personalized cancer treatment approach.

Novelty and Inventive Step

The new claims introduce a synergistic combination of OPCML fragment with AI, IoT, blockchain, and novel nanomaterials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful and effective system for cancer treatment.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different AI algorithms, various IoT-enabled devices, or alternative blockchain platforms. Additionally, the OPCML fragment could be combined with other cancer therapeutic agents or used in conjunction with different types of cancer.

Potential Commercial Applications and Market

The personalized cancer therapy platform has significant commercial potential in the oncology market, with potential applications in ovarian cancer treatment and beyond. The market for cancer therapy is projected to grow significantly in the coming years, and this inventive concept is well-positioned to capitalize on this trend.

CPC Classifications

SectionClassGroup
A A61 A61K39/39558
A A61 A61K31/404
A A61 A61K31/506
A A61 A61K31/517
A A61 A61K31/555
A A61 A61K31/7064
A A61 A61K38/1774
A A61 A61K45/06
C C07 C07K16/28
C C07 C07K16/2863
C C07 C07K16/32
C C12 C12Q1/6886
C C12 C12Q2600/118
C C12 C12Q2600/156
C C12 C12Q2600/158

Field of Art

Oncology, molecular biology, and personalized medicine technologies involving cancer therapeutics, with expertise in protein fragment manipulation, biomarker detection, and advanced computational methods for medical treatment

Person of Ordinary Skill (PHOSITA) Profile

A researcher or medical professional with advanced degrees in molecular biology, biotechnology, or biomedical engineering, possessing expertise in cancer research, computational biology, and emerging medical technologies, familiar with interdisciplinary approaches to therapeutic development

Obviousness Rationale

A person having ordinary skill in the art would recognize that combining the OPCML fragment therapeutic approach with emerging technologies like AI, IoT, and targeted delivery represents a predictable extension of existing cancer treatment methodologies. The source patent establishes the foundational OPCML fragment therapeutic concept, while the published technical disclosure demonstrates straightforward technological integration using well-known computational and medical engineering techniques. The variations represent incremental improvements utilizing standard interdisciplinary approaches common in modern personalized medicine research.

Obvious Combinations & Variations

Source Patent Element
OPCML fragment for cancer therapy targeting specific tumor types
PTD Variation
AI-driven predictive modeling for personalized dosage and treatment duration
Obviousness Reasoning
Applying machine learning to optimize therapeutic protocols is a known technique in precision medicine, representing a predictable application of computational methods to existing therapeutic approaches
Source Patent Element
Cancer therapeutic method using OPCML fragment
PTD Variation
IoT-enabled biosensors for real-time monitoring of OPCML expression levels
Obviousness Reasoning
Integrating continuous biomarker monitoring with targeted therapies is a standard approach in modern personalized medicine, utilizing well-established sensor and data transmission technologies
Source Patent Element
OPCML fragment administration method
PTD Variation
Targeted nanomaterial delivery system for enhanced OPCML fragment uptake
Obviousness Reasoning
Developing advanced drug delivery mechanisms is a routine optimization strategy in pharmaceutical research, representing a predictable enhancement to existing therapeutic approaches
Source Patent Element
Cancer therapeutic protein fragment method
PTD Variation
Blockchain-based platform for secure research data sharing
Obviousness Reasoning
Implementing secure, decentralized data management in medical research is a standard technological approach for collaborative scientific investigation
Source Patent Element
Cancer treatment using protein fragments
PTD Variation
Machine learning algorithms for identifying novel therapeutic targets
Obviousness Reasoning
Applying computational methods to discover new therapeutic approaches is a well-established technique in molecular biology and medical research
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857624 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent predictable combinations of known therapeutic approaches with standard computational and medical engineering techniques. The disclosed methods constitute prior art demonstrating that the integration of OPCML fragment therapy with AI, IoT, blockchain, and targeted delivery technologies would be obvious to a skilled practitioner in the field of oncological research and personalized medicine.

Original Patent Information

Patent NumberUS 11,857,624
TitleCancer therapeutic methods utilizing OPCML fragment
Assignee(s)PAPYRUS THERAPEUTICS, INC.